Astellas Pharma (OTCPK:ALPM.F) - Stock Price, News & Analysis

ALPM.F Stock Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.

ALPM.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 68.4% below our estimate of its fair value

Earnings are forecast to grow 32.89% per year

Risk Analysis

Dividend of 4.78% is not well covered by earnings or cash flows

Profit margins (0.3%) are lower than last year (9.3%)

Large one-off items impacting financial results

Astellas Pharma Inc. Competitors

Royalty Pharma

NasdaqGS:RPRX

US$16.5b

Viatris

NasdaqGS:VTRS

US$13.2b

Teva Pharmaceutical Industries

NYSE:TEVA

US$14.9b

Catalent

NYSE:CTLT

US$10.1b

Price History & Performance

Summary of all time highs, changes and price drops for Astellas Pharma
Historical stock prices
Current Share Price	JP¥9.17
52 Week High	JP¥17.00
52 Week Low	JP¥9.13
Beta	0.28
1 Month Change	-17.31%
3 Month Change	-23.82%
1 Year Change	-38.25%
3 Year Change	-39.45%
5 Year Change	-35.11%
Change since IPO	-68.52%

Recent updates

Shareholder Returns

	ALPM.F	US Pharmaceuticals	US Market
7D	-11.4%	-2.2%	-3.7%
1Y	-38.2%	11.6%	20.5%

Return vs Industry: ALPM.F underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.

Return vs Market: ALPM.F underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is ALPM.F's price volatile compared to industry and market?
ALPM.F volatility
ALPM.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ALPM.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ALPM.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1923	14,484	Naoki Okamura	www.astellas.com

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.

Astellas Pharma Inc. Fundamentals Summary

How do Astellas Pharma's earnings and revenue compare to its market cap?
ALPM.F fundamental statistics
Market cap	US$16.99b
Earnings (TTM)	US$27.15m
Revenue (TTM)	US$9.98b

625.9x

P/E Ratio

1.7x

P/S Ratio

Is ALPM.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALPM.F income statement (TTM)
Revenue	JP¥1.54t
Cost of Revenue	JP¥281.54b
Gross Profit	JP¥1.26t
Other Expenses	JP¥1.26t
Earnings	JP¥4.20b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)	2.34
Gross Margin	81.76%
Net Profit Margin	0.27%
Debt/Equity Ratio	58.1%

How did ALPM.F perform over the long term?

See historical performance and comparison

Dividends

4.8%

Current Dividend Yield

2,783%

Payout Ratio

ALPM.F Stock Overview

Rewards

Risk Analysis

Astellas Pharma Inc. Competitors

NasdaqGS:RPRX

US$16.5b

NasdaqGS:VTRS

US$13.2b

NYSE:TEVA

US$14.9b

NYSE:CTLT

US$10.1b

Price History & Performance

Recent News & Updates

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Recent updates

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol

U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials

Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant

Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial

Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab

Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause

Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S

Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease

Astellas Pharma Inc. Presents Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium

Astellas Pharma Inc. Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions

Astellas Pharma Inc. to Report Q3, 2023 Results on Feb 06, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3 GLOW Clinical Trial

Astellas Pharma Inc. Appoints Steve Sabus as Chief Commercial Officer

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Astellas Pharma Inc. Announces Skylight 4™ Study Results Demonstrate the 52-Week Safety and Tolerability of Fezolinetant 30 Mg and 45 Mg Once Daily

European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Application for Fezolinetant

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China